Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
108
-
Total 13F shares, excl. options
-
40.1M
-
Shares change
-
-22.4K
-
Total reported value, excl. options
-
$561M
-
Value change
-
-$19.1M
-
Number of buys
-
62
-
Number of sells
-
-51
-
Price
-
$14.01
Significant Holders of Nurix Therapeutics, Inc. - Common Stock (NRIX) as of Q1 2022
133 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock as of Q1 2022.
Nurix Therapeutics, Inc. - Common Stock (NRIX) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.1M shares
of 76.6M outstanding shares and own 52.27% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.81M shares), Redmile Group, LLC (3.02M shares), BlackRock Inc. (2.52M shares), BAKER BROS. ADVISORS LP (2.45M shares), STATE STREET CORP (2.3M shares), VANGUARD GROUP INC (2.03M shares), TRV GP III, LLC (1.92M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.87M shares), WASATCH ADVISORS INC (1.55M shares), and PICTET ASSET MANAGEMENT SA (1.44M shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.